文献速递艾滋病与性传播感染

rhIL-15联合抗PD-L1在SIV感染猕猴中扩增CXCR3+PD1-/low CD8 T细胞

Recombinant Human Interleukin-15 and Anti-PD-L1 Combination Therapy Expands a CXCR3+PD1-/low CD8 T-Cell Subset in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
PubMed 文献 · J Infect Dis · 2020-01-01

本研究在接受cART的SIV感染猕猴中联合使用抗PD-L1(Avelumab)与重组人IL-15,评估安全性、免疫学参数和病毒载量。治疗安全耐受,可短暂增加增殖性NK和CD8 T细胞,并扩增具细胞因子分泌能力的CXCR3+PD1-/low CD8 T细胞亚群,但cART中断后血浆病毒血症无变化。

要点

  • rhIL-15联合抗PD-L1在SIV感染猕猴中安全耐受。
  • 治疗扩增具功能的CXCR3+PD1-/low CD8 T细胞亚群。
  • cART中断后血浆病毒血症未见变化。

核心结论

  • 在SIV感染猕猴中扩增具功能且可能迁移至病毒储存库的CXCR3+PD1-/low CD8 T细胞亚群,对cART中断后血浆病毒血症无明显影响。

研究设计与样本

  • 在接受了cART的SIV感染猕猴中,rhIL-15以连续输注方式给予2个10天周期,同时每周给予抗PD-L1(Avelumab),监测安全性、免疫学参数和病毒载量。

主要发现

  • rhIL-15/抗PD-L1给药安全且耐受良好。
  • 治疗导致增殖性(Ki67+)自然杀伤细胞和CD8 T细胞短暂增加。
  • 治疗扩增了具有细胞因子分泌能力的CXCR3+PD1-/low CD8 T细胞亚群。
  • cART中断后血浆病毒血症未见变化。

临床怎么用

  • 该联合方案在SIV模型中安全且可扩增特定CD8 T细胞亚群,但未显示对cART中断后病毒血症的控制作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The PD1/PD-L1 pathway contributes to the pathogenesis of human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) infection, and blockade of this pathway may have potential to restore immune function and promote viral control or elimination. In this study, we combined a checkpoint inhibitor anti-PD-L1 (Avelumab) and recombinant human interleukin-15 (rhIL-15) in SIV-infected rhesus macaques (RM). METHODS: The rhIL-15 was administered as continuous infusion in 2 cycles of 10 days in the context of weekly administration of anti-PD-L1 (Avelumab) in SIV-infected RM receiving combination antiretroviral therapy (cART). Safety, immunological parameters, and viral loads were monitored during the study. RESULTS: Administration of rhIL-15/anti-PD-L1 was safe and well tolerated. Treatment resulted in transient increases in proliferating (Ki67+) natural killer and CD8 T cells. In addition, treatment expanded a CXCR3+PD1-/low CD8 T-cell subset with the ability to secrete cytokines. Despite these effects, no changes in plasma viremia were observed after cART interruption. CONCLUSIONS: Expansion of the CXCR3+PD1-/low CD8 T-cell subset with functional capacity and potential to traffic to sites of viral reservoirs in SIV-infected rhesus macaques had no demonstrable effect on plasma viremia after cART interruption.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chen P, Chen H, Moussa M, et al. Recombinant Human Interleukin-15 and Anti-PD-L1 Combination Therapy Expands a CXCR3+PD1-/low CD8 T-Cell Subset in Simian Immunodeficiency Virus-Infected Rhesus Macaques. J Infect Dis. 2020. PMID: 31562760. doi:10.1093/infdis/jiz485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。